Radioimmunoassay (RIA) for the determination of human free anti-insulin antibodies (AIA) in serum and plasma. FDA registered 510(k) Exempt. For In-Vitro Diagnostic Use
The presence of circulating anti-insulin antibodies (AIA) in diabetics treated with insulin has been recognized as early as 1955. The highly purified insulin preparations, presently available, are less immunogenic than some of the previously used, less pure, preparations. Bovine insulin is more immunogenic than the porcine hormone. Also, it has recently been recognized that AIA may develop, in patients treated with human insulin. The determination of circulating anti-insulin antibodies is of clinical importance for the following reasons:The presence of free anti-insulin antibodies in plasma interferes with the determination of insulin by radioimmunoassay;<br><br>
- At very high titers, the anti-insulin antibodies may induce a state of insulin resistance;
- Anti-insulin antibodies may influence the quality of the glycemic control, in diabetic patients, by prolonging the half life of insulin.
- Assay Description:
- 2 hour incubation (37°C) + 15 min. (RT) + 15 min. Centrifuge (RT) = 2 hours, 30 min. total incubation time
- Catalog number:
- KIP0091
- configuration:
- Reagents sufficient for 96 determinations
- controls:
- 3 controls, lyophilized
- design:
- Radioimmunoassay (RIA) technique
- FDA Status:
- For research use only, not for use in diagnostic procedures
- MSDS:
- notes:
- The protocol for this product (see above) is intended to serve as an example only. Please refer to the Instructions For Use provided with the assay kit for precise details.
- Other names:
- Free anti-insulin antibodies (AIA)
- Protocol:
- Sample types:
- Serum, Plasma
- Sample volume:
- 100 μL / determination
- standards:
- None provided
- Standard range:
- 0 - 100%
- storage:
- 2 - 8 °C
- sensitivity:
- Please see protocol for assay-specific performance characteristics
- Species:
- Human
- radioactivity:
- 2 µCi (74 kBq)
